While much of the focus has been on the mergers and acquisitions at this year’s JP Morgan Healthcare conference, seeing what a few companies have up their sleeves is also intriguing.
In today’s round up we address reader Q&A as well as highlight some presentations and announcements of interest in the cancer research space.
2019 is going to turn out to be a rather critical year for some companies…
If you missed the first day’s highlights and lowlights – check them out here!
To learn more and get a heads up on our latest conference coverage, subscribers can log-in or you can click to gain access to BSB Premium Content.
For the last couple of years at every annual meeting of the American Society of Hematology (ASH) conference, I have posted an extensive Preview of the CAR T cell therapy landscape and looked at which abstracts piqued my interest.
The roaring 30s CAR
This year the review is the most extensive to date, with more companies, more research groups, more tumour types and way more preclinical research coming through. It’s like a kaleidoscope of ideas cascading through R&D.
The other thing to take note is how fast the field is moving – it’s warp speed now and so much comes through the literature every month on top of that.
So here we go – hold onto your hats as there is a LOT to contemplate this year!
To get a heads up and learn more insights, subscribers can log-in or you can click to gain access to BSB Premium Content.